Structure: BIEL licenses its Pulsed Shortwave Therapy (PSWT) technology (used in ActiPatch and RecoveryRx) to Electrome. Electrome gains access to clinically validated tech without reinventing the wheel. BIEL monetizes its IP and expands its market reach. Electrome withdraw their FDA application because of Biel's already approved Actipatch!